APUS

Company Overview — What Does Apimeds Pharmaceuticals US, Inc. Do?

We are a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects. Apitox is currently marketed and sold by Apimeds Inc. (“Apimeds Korea”) in the South Korea as “Apitoxin.” Apimeds US is not associated with the market, sale and revenues generated from Apitoxin in South Korea, and Apitoxin has not been approved by the U.S. Food and Drug Administration (the “FDA”) for any indication. Apimeds is currently developing Apitox as a potential osteoarthritis (“OA”) treatment for patients with knee pain who failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics. In 2003, after completing successful Phase I, II, and III trials, the Korean Ministry of Food and Drug Safety (the “MFDA”) approved the use of Apitoxin to treat pain and mobility in patients with OA in South Korea. Apitoxin has been used in the South Korea to treat the reduction of pain associated with OA since 2003. Additionally, a post-marketing/approval safety study in South Korea followed 3,194 patients from 2003 through 2009, with no serious adverse events. In 2013, the FDA authorized Apimeds Korea to conduct a preliminary Phase III to study the same indication approved in South Korea — the use of Apitoxin to treat pain and inflammation in patients with OA — which was completed in 2018 (the “Apimeds Korea Phase III OA Trial”). On August 2, 2021, we entered into an agreement with Apimeds Korea, a principal stockholder of Apimeds US (the “Business Agreement”). Pursuant to the Business Agreement, Apimeds Korea granted to the Company a sublicensable, royalty-bearing license to utilize all prior clinical development data associated with Apitoxin, Apitox, and all related names, and to advance clinical research, develop, manufacture and commercialize and sell Apitox in the United States. Based on the results from the Apimeds Korea Phase III OA Trial, which demonstrated therapeutic effect in the treatment group compared to the placebo group, but in combination with prior development by Apimeds Korea, did not meet the FDA’s standards for approval, as the study population was too small and the methods for handling missing data were inadequate, resulting in a study that did not demonstrate a significant treatment effect. We will be pursuing a second Phase III trial to meet agreed upon FDA standards. Based on results from the Apimeds Korea Phase III OA Trial, we have evaluated the most appropriate population, defined as advanced knee OA patients, which will range from defined grade 2, 3 and 4 within this treatment group, to continue to progress our own Phase III trial in knee OA. Pursuant to our previous correspondence with the FDA, we have designed and will implement our Phase III trial to best address our patient population, appropriate dosing, and the most effective way to evaluate Apitox in meeting the patient population’s needs. Apimeds Korea has also engaged in clinical trials to explore the therapeutic effect of Apitoxin in patients with multiple sclerosis (“MS”), including in 2014, submitting an Investigational New Drug Application (“IND”) 122804 to run a Phase III clinical trial. Pursuant to the Business Agreement, Apimeds Korea transferred sponsorship of IND 122804 to Apimeds US in October 2020. Pursuant to the written correspondence from the FDA, as of the date of this prospectus, there are no clinical holds relating to the planned clinical trials. However, we have made the strategic decision to focus our MS efforts on the early prosecution of appropriate patient populations through non-registered corporate sponsorship studies and will not be pursuing a Phase III trial for MS at this time. Chronic diseases such as OA and MS cause considerable economic, personal, and societal burden. These diseases negatively impact quality of life and progress from the time of onset until death. We are dedicated to developing innovative therapies using Apitox that seek to restore the health and enhance the quality of life of patients suffering with these diseases. To this date, Apimeds has generated no revenue from the sale and or distribution of Apitox in the United States. We have generated our clinical data and an opportunity to advance treatment opportunities with proceeds received from sales of our securities to prior investors and the work of our partners, Apimeds Korea and Inscobee Inc. We do not currently hold any debt as prior investments in the form of convertible notes have since been converted to equity. We believe that naturalized bee venom can provide an additive treatment, that pending clinical demonstration of success and FDA approval, could provide value to OA patients in need and the physicians treating OA patients, and potentially MS. The advancement of Apitox as a candidate and Apimeds as a company, will be dictated by the clinical data and the regulatory agencies interpretation of such data in regard to effectiveness, safety and potential benefit beyond existing treatment options. Apimeds US was incorporated in Delaware on May 11, 2020. We are located at 2 East Broad Street, 2nd Floor, Hopewell, New Jersey. Apimeds Pharmaceuticals US, Inc. (APUS) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Erik C. Emerson and employs approximately 2 people, headquartered in HOPEWELL, New Jersey. With a market capitalization of $2M, APUS is one of the notable companies in the Healthcare sector.

Apimeds Pharmaceuticals US, Inc. (APUS) Stock Rating — Reduce (April 2026)

As of April 2026, Apimeds Pharmaceuticals US, Inc. receives a Reduce rating with a composite score of 31.2/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.APUS ranks #3,895 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Apimeds Pharmaceuticals US, Inc. ranks #664 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

APUS Stock Price and 52-Week Range

Apimeds Pharmaceuticals US, Inc. (APUS) currently trades at $1.71. The stock gained $0.05 (3.0%) in the most recent trading session. The 52-week high for APUS is $4.03, which means the stock is currently trading -57.6% from its annual peak. The 52-week low is $0.95, putting the stock 79.8% above its annual trough. Recent trading volume was 117K shares, suggesting relatively thin trading activity.

Is APUS Overvalued or Undervalued? — Valuation Analysis

Apimeds Pharmaceuticals US, Inc. (APUS) carries a value factor score of 11/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.90x, versus the sector average of 2.75x.

At current multiples, Apimeds Pharmaceuticals US, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Apimeds Pharmaceuticals US, Inc. Profitability — ROE, Margins, and Quality Score

Apimeds Pharmaceuticals US, Inc. (APUS) earns a quality factor score of 28/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -87.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -77.0% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

APUS Debt, Balance Sheet, and Financial Health

Apimeds Pharmaceuticals US, Inc. has a debt-to-equity ratio of 13.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 8.34x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $7M.

APUS has a beta of -0.29, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Apimeds Pharmaceuticals US, Inc. is 27/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Apimeds Pharmaceuticals US, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Apimeds Pharmaceuticals US, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.14. Net income for the quarter was $-2M. Operating income came in at $-2M.

In Q3 2025, Apimeds Pharmaceuticals US, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.14. Net income for the quarter was $-2M. Operating income came in at $-2M.

In Q2 2025, Apimeds Pharmaceuticals US, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.26. Net income for the quarter was $-3M. Operating income came in at $-3M.

In Q1 2025, Apimeds Pharmaceuticals US, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.05. Net income for the quarter was $-402,397. Operating income came in at $-364,368.

Over the past 6 quarters, Apimeds Pharmaceuticals US, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing APUS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

APUS Dividend Yield and Income Analysis

Apimeds Pharmaceuticals US, Inc. (APUS) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

APUS Momentum and Technical Analysis Profile

Apimeds Pharmaceuticals US, Inc. (APUS) has a momentum factor score of 37/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 69/100 reflects moderate short selling activity.

APUS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Apimeds Pharmaceuticals US, Inc. (APUS) ranks #664 out of 838 stocks based on the Blank Capital composite score. This places APUS in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing APUS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full APUS vs S&P 500 (SPY) comparison to assess how Apimeds Pharmaceuticals US, Inc. stacks up against the broader market across all factor dimensions.

APUS Next Earnings Date

No upcoming earnings date has been announced for Apimeds Pharmaceuticals US, Inc. (APUS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy APUS? — Investment Thesis Summary

The quantitative profile for Apimeds Pharmaceuticals US, Inc. suggests caution. The quality score of 28/100 flags below-average profitability. The value score of 11/100 indicates premium valuation. Momentum is weak at 37/100, a headwind for near-term performance. High volatility (stability score 27/100) increases portfolio risk.

In summary, Apimeds Pharmaceuticals US, Inc. (APUS) earns a Reduce rating with a composite score of 31.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on APUS stock.

Related Resources for APUS Investors

Explore more research and tools: APUS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare APUS head-to-head with peers: APUS vs AZN, APUS vs SLGL, APUS vs VMD.